One Percent Rule Checklist For Safer Forex Trading Risk 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
DENVER, April 17, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) announced today that the Company will release its first quarter 2017 financial results on Thursday, May 4, 2017, before the opening of the U.S. financial markets.
Daniel E. Greenleaf, President and Chief Executive Officer, and Jeffrey M. Kreger, Senior Vice President, Chief Financial Officer and Treasurer, will conduct a conference call as follows:
| Date | Thursday, May 4, 2017 | |
| Time | 9:00 a.m. EDT | |
| Toll free (U.S.) | (888) 372-9592 | |
| Webcast (live and replay) | www.bioscrip.com | |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (US) and entering conference call ID number 8579499.
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home healthcare management solutions. BioScrip partners with healthcare providers, including physicians, hospital systems, skilled nursing facilities, and with healthcare payors to provide patients better access to high quality, efficient post-acute care services. BioScrip operates with a commitment to bring infusion therapy services into the home or alternate-site settings. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.
Investor Contacts: Jeffrey M. Kreger Chief Financial Officer T: (720) 697-5200 [email protected] David Clair ICR, Inc. T: (646) 277-1266 [email protected]
